Skip to content

EV Biologics

EV Biologics to Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University

EV Biologics, Inc. formerly Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it intends to utilize the advanced instrumentation and research staff at the Vanderbilt Institute of Nanoscale Science and Engineering (VINSE) and the Vanderbilt Center for Structural Biology (CSB) in the development of extracellular vesicle (EV)-based diagnostics and therapeutics.

Founded in 1873, Vanderbilt University located in Nashville, Tennessee is a pre-eminent and legendary private research university comprised of 10 distinct schools and colleges on one centralized campus. Regularly ranked as one of the nation’s top 15 universities by publications such as “U.S. News & World Report”, with programs that rank in the top 10, Vanderbilt is a world-class institution. The University was recently ranked #10 in Reuter’s assessment of the World’s Most Innovative Universities. (Source: Vanderbilt University Website –

Quality Control (QA/QC) is the cornerstone of the Company’s plan for Current Good Manufacturing Practices cGMP development of EV diagnostics and therapeutic products. The Vanderbilt CSB and VINSE are extraordinary research facilities that have the capability of performing nanoscale analytical methods such as Atomic Force Microscopy, Electron Microscopy and Nano Tracking Analysis. The Vanderbilt University research staff has extensive experience with nanoparticle characterization methods that will form an essential part of QA/QC for the Company’s therapeutic development.

The Company is making a significant investment in its own analytical equipment to facilitate novel solutions to overcome the challenges in EV product characterization and standardization. EV analysis performed by research staff at Vanderbilt will complement and confirm the Company’s own EV development data and will provide the orthogonal characterization for EV research recommended by the International Society for Extracellular Vesicles.

CMO, Dr. Jason Sanders, said “having access to this kind of extremely specialized instrumentation and experts in nanoparticle analysis at such a highly respected institution as Vanderbilt will be instrumental in advancing our R&D program for biopharmaceuticals and will enable meticulous analysis for preparation of Investigational New Drug applications (IND’s) to the FDA for maximum efficiency in EV drug development.”

The Company is currently in the process of getting a new trading symbol with FINRA after successfully getting our name changed. Our goal is to become current in our OTC filings by the end of October with OTC Markets

About the Company

EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal “MSC” and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.

Forward-Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans,” “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think,” “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

YECO has 6.21 million shares issued and outstanding with a float of 1,016,375 shares.